trial

PREvent First Episode Relapse (PREFER)

NCTId NCT00220714
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 80
Sponsored by State University of New York - Downstate Medical Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
80
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2004-11
Primary completion
—
Eligibility
ALL · 16 Years · 50 Years

Interventions & indications

Drugs
atypical antipsychotics:oral vs. long-acting routeFamily psychoeducation

Sponsors

State University of New York - Downstate Medical CenterLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
Peter Handest, MD, Ph.d.Principal Investigator

Sites

2 total
Brooklyn, United StatesBrooklyn, United States

Facts & assertions

3 sourced
Enrollment
80
Phase
PHASE4
Status
UNKNOWN
relationships
The graph out of here
drug
atypical antipsychotics:oral vs. long-acting route
drug
Family psychoeducation
drug
lead_sponsor
State University of New York - Downstate Medical Center
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication
Patient Compliance
indication
investigator
Peter Handest, MD, Ph.d.
person